AGC Biologics, AdaptVac partner on COVID-19 vaccine

By The Science Advisory Board staff writers

AGC Biologics, a contract development and manufacturing organization, and AdaptVac have teamed up to develop a COVID-19 vaccine.

The companies, along with the European Union Horizon 2020-sponsored Prevent-nCoV consortium partners, will use AdaptVac's virus-like particle technology to develop the vaccine. This technology makes ideal scaffolds for displaying vaccine antigens due to their particulate nature and dense repetitive subunit organization, according to the companies.

Clinical trials are expected to begin in late-2020.

Copyright © 2020

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking